Skip to main content
Advertisement
Advertisement

SMMT

SMMT logo

Summit Therapeutics Inc. Common Stock

17.59
USD
Sponsored
+0.42
+2.45%
Oct 09, 15:59 UTC -4
Closed
exchange

After-Market

17.59

0.00
+0.03%

SMMT Earnings Reports

Positive Surprise Ratio

SMMT beat 4 of 16 last estimates.

25%

Next Report

Date of Next Report
Oct 19, 2026
Estimate for Q3 26 (Revenue/ EPS)
$68.00K
/
-$0.29
Implied change from Q2 26 (Revenue/ EPS)
--
/
+3.57%
Implied change from Q3 25 (Revenue/ EPS)
--
/
-6.45%

Summit Therapeutics Inc. Common Stock earnings per share and revenue

On Jul 23, 2026, SMMT reported earnings of -0.28 USD per share (EPS) for Q2 26, beating the estimate of -0.28 USD, resulting in a 1.72% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -8.81% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of -0.29 USD, with revenue projected to reach 68.00 thousand USD, implying an increase of 3.57% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
NanoViricides Inc.
Report Date
Sep 28, 2026 For Q4 26
Estimate
-$0.10
Actual
-$0.10
Surprise
+1.96%
FAQ
For Q2 2026, Summit Therapeutics Inc. Common Stock reported EPS of -$0.28, beating estimates by 1.72%, and revenue of $0.00, 0% as expectations.
The stock price moved down -8.81%, changed from $14.98 before the earnings release to $13.66 the day after.
The next earning report is scheduled for Oct 19, 2026.
Based on -- analysts, Summit Therapeutics Inc. Common Stock is expected to report EPS of -$0.29 and revenue of $68.00K for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement